Quality of life in patients with rheumatoid arthritis during rituximab therapy
Objective: to evaluate the effect of rituximab (RTM) on quality of life (QL) in patients with rheumatoid arthritis (RA) from the results of EQ-5D questionnaire total scores. Subjects and methods. Ninety-eighty patients with a valid diagnosis of RA were followed up. All the patients were randomized t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/481 |
| _version_ | 1797876837327568896 |
|---|---|
| author | Tatiana Alekseyevna Raskina M V Koroleva |
| author_facet | Tatiana Alekseyevna Raskina M V Koroleva |
| author_sort | Tatiana Alekseyevna Raskina |
| collection | DOAJ |
| description | Objective: to evaluate the effect of rituximab (RTM) on quality of life (QL) in patients with rheumatoid arthritis (RA) from the results of EQ-5D questionnaire total scores. Subjects and methods. Ninety-eighty patients with a valid diagnosis of RA were followed up. All the patients were randomized to two groups according to the basic therapy option: 1) 56 patients on combination therapy with methotrexate (MT; mean dose 13.72±0.06 mg weekly) and rituximab (RTM) by the standard regimen; 2) 42 patients receiving only MT (mean dose 12.6±0.08 mg weekly). The follow-up was 24 months. The international EQ-5D questionnaire was employed to assess QL. Results. While filling out the EQ-5D questionnaire, all the patients with RA mentioned baseline health problems to one extent or another. One year after therapy, there was a statistically significant increase in health index in both Groups 1 and 2: 0.61±0.04 and 0.63±0.07 (р<0.05 and р<0.05, respectively). Group 1 showed a statistically significant rise in VAS scores at 12 (46.7±6.3 mm; р<0.05) and 24 (49.3±11.4 mm; р<0.05) months versus at baseline. Conclusion. There was a satisfactory therapeutic effect only in the MT + RTM combination group whereas there was a minimal one in the MT monotherapy group. |
| first_indexed | 2024-04-10T02:07:36Z |
| format | Article |
| id | doaj.art-832152eb2e0f4242a39940ce03fc2985 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:07:36Z |
| publishDate | 2013-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-832152eb2e0f4242a39940ce03fc29852023-03-13T08:39:23ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2013-06-0172576110.14412/1996-7012-2013-23831786Quality of life in patients with rheumatoid arthritis during rituximab therapyTatiana Alekseyevna RaskinaM V KorolevaObjective: to evaluate the effect of rituximab (RTM) on quality of life (QL) in patients with rheumatoid arthritis (RA) from the results of EQ-5D questionnaire total scores. Subjects and methods. Ninety-eighty patients with a valid diagnosis of RA were followed up. All the patients were randomized to two groups according to the basic therapy option: 1) 56 patients on combination therapy with methotrexate (MT; mean dose 13.72±0.06 mg weekly) and rituximab (RTM) by the standard regimen; 2) 42 patients receiving only MT (mean dose 12.6±0.08 mg weekly). The follow-up was 24 months. The international EQ-5D questionnaire was employed to assess QL. Results. While filling out the EQ-5D questionnaire, all the patients with RA mentioned baseline health problems to one extent or another. One year after therapy, there was a statistically significant increase in health index in both Groups 1 and 2: 0.61±0.04 and 0.63±0.07 (р<0.05 and р<0.05, respectively). Group 1 showed a statistically significant rise in VAS scores at 12 (46.7±6.3 mm; р<0.05) and 24 (49.3±11.4 mm; р<0.05) months versus at baseline. Conclusion. There was a satisfactory therapeutic effect only in the MT + RTM combination group whereas there was a minimal one in the MT monotherapy group.https://mrj.ima-press.net/mrj/article/view/481ревматоидный артритритуксимабкачество жизниопросник eq-5d |
| spellingShingle | Tatiana Alekseyevna Raskina M V Koroleva Quality of life in patients with rheumatoid arthritis during rituximab therapy Современная ревматология ревматоидный артрит ритуксимаб качество жизни опросник eq-5d |
| title | Quality of life in patients with rheumatoid arthritis during rituximab therapy |
| title_full | Quality of life in patients with rheumatoid arthritis during rituximab therapy |
| title_fullStr | Quality of life in patients with rheumatoid arthritis during rituximab therapy |
| title_full_unstemmed | Quality of life in patients with rheumatoid arthritis during rituximab therapy |
| title_short | Quality of life in patients with rheumatoid arthritis during rituximab therapy |
| title_sort | quality of life in patients with rheumatoid arthritis during rituximab therapy |
| topic | ревматоидный артрит ритуксимаб качество жизни опросник eq-5d |
| url | https://mrj.ima-press.net/mrj/article/view/481 |
| work_keys_str_mv | AT tatianaalekseyevnaraskina qualityoflifeinpatientswithrheumatoidarthritisduringrituximabtherapy AT mvkoroleva qualityoflifeinpatientswithrheumatoidarthritisduringrituximabtherapy |